Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab.

MLA

Agulló-Ortuño, M.Teresa, et al. “Blood Predictive Biomarkers for Patients With Non-Small-Cell Lung Cancer Associated With Clinical Response to Nivolumab.” Clinical Lung Cancer, vol. 21, no. 1, Jan. 2020, pp. 75–85. EBSCOhost, https://doi.org/10.1016/j.cllc.2019.08.006.

APA

Agulló-Ortuño, M. T., Gómez-Martín, Ó., Ponce, S., Iglesias, L., Ojeda, L., Ferrer, I., García-Ruiz, I., Paz-Ares, L., & Pardo-Marqués, V. (2020). Blood Predictive Biomarkers for Patients With Non-small-cell Lung Cancer Associated With Clinical Response to Nivolumab. Clinical Lung Cancer, 21(1), 75–85. https://doi.org/10.1016/j.cllc.2019.08.006

Chicago

Agulló-Ortuño, M Teresa, Óscar Gómez-Martín, Santiago Ponce, Lara Iglesias, Laura Ojeda, Irene Ferrer, Inmaculada García-Ruiz, Luis Paz-Ares, and Virginia Pardo-Marqués. 2020. “Blood Predictive Biomarkers for Patients With Non-Small-Cell Lung Cancer Associated With Clinical Response to Nivolumab.” Clinical Lung Cancer 21 (1): 75–85. doi:10.1016/j.cllc.2019.08.006.